Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CMBusiness Wire • 05/04/26
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y GrowthZacks Investment Research • 05/01/26
Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter YearSeeking Alpha • 05/01/26
Alnylam Pharmaceuticals (ALNY) Tops Q1 Earnings and Revenue EstimatesZacks Investment Research • 04/30/26
Alnylam Pharma Surges After Sales Of Its Biggest Moneymaker CatapultInvestors Business Daily • 04/30/26
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period ProgressBusiness Wire • 04/30/26
Alnylam (ALNY) Q1 Earnings Preview: What You Should Know Beyond the Headline EstimatesZacks Investment Research • 04/29/26
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 04/23/26
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial ResultsBusiness Wire • 04/16/26
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock?Zacks Investment Research • 04/07/26
An S&P 500 change may be imminent. These stocks are leading contenders to join the index.Market Watch • 04/06/26
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension ManagementBusiness Wire • 03/30/26
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR Franchise TranscriptSeeking Alpha • 03/24/26
Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac AmyloidosisBusiness Wire • 03/24/26
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart AssociationBusiness Wire • 03/24/26
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatmentsReuters • 03/05/26